Trial Profile
A phase II study of anti-CD52 monoclonal antibody (Alemtuzumab, MabCampath) with 2-weekly CHOP chemotherapy (Camp-CHOP 14) in patients with mature T-cell non-Hodgkins lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Pegfilgrastim; Prednisolone; Prednisone; Vincristine
- Indications Extranodal NK-T-cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- 14 Jul 2010 New trial record